Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-13T02:59:42.495Z Has data issue: false hasContentIssue false
  • English
  • Français

Assessing the Risk of Health, Social, and Fiscal Events in Schizophrenia According to Remission or Relapse Status Using Real World Data from a SCZ Survey in the US

Published online by Cambridge University Press:  28 April 2022

Aditi Kadakia ,
Rui Martins ,
Angela Fan ,
Carole Dembek ,
Mark Connolly ,
Jason Shepherd  and
Rhys Williams
Aditi Kadakia
Affiliation:
Sunovion Pharmaceuticals Inc., Marlborough, MA, USA
Rui Martins
Affiliation:
Health Economics, Global Market Access Solutions Sarl, St-Prex, Switzerland
Angela Fan
Affiliation:
Sunovion Pharmaceuticals Inc., Marlborough, MA, USA
Carole Dembek
Affiliation:
Sunovion Pharmaceuticals Inc., Marlborough, MA, USA
Mark Connolly
Affiliation:
Health Economics, Global Market Access Solutions Sarl, St-Prex, Switzerland Unit of Pharmacoepidemiology & Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
Jason Shepherd
Affiliation:
Adelphi Real World, Bollington, United Kingdom
Rhys Williams
Affiliation:
Sunovion Pharmaceuticals Inc., Marlborough, MA, USA
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background

Schizophrenia-related, health, social, and fiscal consequences are substantial, affecting patients, caregivers, and society. The incidence of health, social, and fiscal outcomes are frequently reported for the overall schizophrenia population, not stratified by remission or relapse status.

Objectives

This study aimed to assess healthcare resource use, employment status, and housing circumstances for patients with schizophrenia in remission or relapse, compared to the overall schizophrenia population.

Methods

The Adelphi Schizophrenia Disease Specific Programme was a point-in-time survey conducted across the USA between July and October 2019. Remission was defined using Clinical Global Impression-Severity (CGI-S) score of 1-3 (stable), with relapse defined as a CGI-S score of 4-7 (unstable). Outcome-specific rate ratios were calculated by dividing the cumulative incidence for those in remission or relapse by the cumulative incidence of the overall schizophrenia population. Ratios greater than 1 indicate a higher probability of the event.

Results

Psychiatrists (n = 124) provided data for 409 patients in remission and 609 patients in relapse. Patients with schizophrenia in remission were more likely to be employed (1.66, 95% confidence interval [1.46-1.90]) and to live with a partner or family (1.08 [1.01-1.17]) compared to the overall schizophrenia population, whereas patients in relapse were more likely to experience hospitalizations in the previous 12 months (1.34 [1.19-1.15]), disability-related unemployment (1.38 [1.25-1.51]), sick leave absences (1.23 [0.66-2.31]), need to support housing (1.39 [1.08-1.79]), and homelessness (1.47 [0.95-2.27]).

Conclusions

Schizophrenia patients in relapse were more likely to experience hospitalizations, unemployment, and have unfavorable housing circumstances compared to the overall schizophrenia population. Identifying patients at risk of relapse may aid physicians in targeting interventional support, thereby reducing the burden of schizophrenia.

Funding

Sunovion Pharmaceuticals

Type
Abstracts
Information
CNS Spectrums , Volume 27 , Issue 2 , April 2022 , pp. 225 - 226
Copyright
© The Author(s), 2022. Published by Cambridge University Press